Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

Steven G DuBoisYael P MosseElizabeth FoxRachel A KudgusJoel M ReidRenee McGovernSusan GroshenRochelle BagatellJohn M MarisClare J TwistKelly GoldsmithM Meaghan GrangerBrian D WeissJulie R ParkMargaret E MacySusan L CohnGreg YanikLars M WagnerRandall HawkinsJesse CourtierHollie LaiFariba GoodarzianHiroyuki ShimadaNajee BoucherScarlett CzarneckiChunqiao LuoDenice Tsao-WeiKatherine K MatthayAraz Marachelian

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

This combination shows antitumor activity, particularly in patients with MYCN nonamplified tumors. Data on an alisertib oral solution expand the population able to be treated with this agent.

Keyphrases

acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
newly diagnosed
electronic health record
multiple myeloma
hodgkin lymphoma
big data
randomized controlled trial
machine learning
data analysis
placebo controlled
double blind